Observed arrival · 2026-09-29
Regenaris’s muscle-derived vesicle platform
Regenaris Therapeutics is developing extracellular-vesicle medicines from human muscle progenitor cells, with programs aimed at sarcopenia and Alzheimer’s disease.
- For
- Potential research and development partners
- Worth noticing
- The page names CD9, CD63 and CD81 as identity markers and says characterization follows MISEV guidelines.
Field notes
The described workflow begins with a defined, renewable source of human iPSC-derived muscle progenitor cells. Regenaris says vesicles would be assessed by size, particle count, surface markers, and proteomic cargo profiling, with characterization aligned to MISEV guidelines. The page also lays out organoid and preclinical testing as validation steps; the supplied extract does not report results from those studies or establish a clinical treatment.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
One card from the complete issue